Newly Diagnosed clinical trials

Explore recruiting newly diagnosed clinical trials.

Recruiting newly diagnosed studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Newly Diagnosed trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

HOVON 173 AML: Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy

Austria, Netherlands, Finland, France, Belgium, Sweden +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

HOVON 177: Randomized study to assess revumenib in combination with azacitidine + venetoclax in adult patients with newly diagnosed NPM1 mutated or KMT2A rearranged AML ineligible for intensive chemotherapy

Germany, Netherlands, Austria, Belgium, Denmark, Estonia +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicenter randomized double-blinded controlled phase 2 study evaluating the efficacy of valganciclovir as add-on therapy in glioblastoma patients

Sweden, Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Placebo‐Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts‐2

Germany, Austria, Belgium, Estonia, Finland, Lithuania +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients with Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia (QuANTUM-Wild)

Portugal, Italy, Belgium, Spain, Bulgaria, Croatia +9 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of each of two dose levels of sarilumab in adults with early polymyalgia rheumatica

France, Netherlands, Germany, Czechia, Belgium, Austria +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Newly Diagnosed trials by city

Newly Diagnosed in Toronto Newly Diagnosed in Vancouver Newly Diagnosed in Montreal Newly Diagnosed in Calgary Newly Diagnosed in Edmonton Newly Diagnosed in Ottawa Newly Diagnosed in Winnipeg Newly Diagnosed in Quebec City Newly Diagnosed in Hamilton Newly Diagnosed in Kitchener Newly Diagnosed in London Newly Diagnosed in Halifax Newly Diagnosed in New York Newly Diagnosed in Los Angeles Newly Diagnosed in Chicago Newly Diagnosed in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease